Seeking Alpha·3d ago
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call TranscriptNuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript
Nuvation Bio's recent $31.7M revenue quarter and 97.1% gross margin are driven by milestone payments, not sustainable product sales, as evidenced by the 699% YoY spike from a negligible base.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.12+2.9% vs -$0.12 | $45M+30.7% vs $34M |
Q3 2026 Aug 6, 2026 | -$0.15-5.9% vs -$0.14 | $32M+17.2% vs $27M |
Q2 2026 May 4, 2026 | $0.01+135.7% vs -$0.03 | $83M+25.7% vs $66M |
Q2 2026 Mar 2, 2026 | -$0.11+0.0% vs -$0.11 | $42M+10.7% vs $38M |
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.16 per share a year ago.
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 market leader in new patient starts and total active patients for both first-line and all lines of therapy combined, based on IQVIA claims data FDA approved a supplemental New Drug Application (sNDA) for IBTROZI, updating label to reflect median duration of response of 49.7 months in TKI-naïve ROS1+ NSCLC patients in TRUST-I FDA granted Fast Track Designation to safusidenib for the treatment of IDH1-mutant glioma Cash, cash equivalents, and marketable securities of $663.4 million as of September 30, 2026 Company to host a conference call today at 4:30 p.m. ET NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
Nuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in progress overviews for ongoing safusidenib studies Poster featuring Phase 2 results to be presented at SNO includes additional data beyond topline results previously announced in July 2026 NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2 J201 study and three posters on ongoing studies of safusidenib, its selective investigational inhibitor of mutant IDH1, will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting taking place November 12–15, 2026, in Philadelphia, PA. Positive topline Phase 2 J201 results were announced in July; additional key data will be featured in the SNO poster.
Benchmark NUVB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nuvation Bio Inc. (NUVB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.16 | $1.44B | -10.77 | 698.96% | -67.38% | -49.11% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $0.38 | $5.79M | -0.14 | — | — | -1270.11% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $192.28 | $40.88B | -22.10 | — | -946.82% | -91.93% | — | |
| $16.46 | $2.12B | 7.08 | 20.38% | 97.68% | 51.92% | — |
Nuvation Bio Inc. (NUVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nuvation Bio Inc. (NUVB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 6, 2026·SEC
Jun 30, 2026·SEC
Get notified when NUVB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nuvation Bio Inc. (NUVB) stock FAQ — growth, dividends, profitability & financials explained
Nuvation Bio Inc. (NUVB) reported $201.7M in revenue over the trailing twelve months. Revenue was $62.9M in fiscal year 2025.
Nuvation Bio Inc. (NUVB) grew revenue by 654.2% over the trailing twelve months, compared with the twelve months before.
No. Nuvation Bio Inc. (NUVB) reported a net loss of $135.9M over the trailing twelve months.
Nuvation Bio Inc. (NUVB) had a return on equity (ROE) of -49.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
Nuvation Bio Inc. (NUVB) had negative free cash flow of $108.2M over the trailing twelve months.
